Intersect ENT

169 articles with Intersect ENT

• 

  FDA Green Lights Intersect ENT's SINUVA Sinus Implant

  12/11/2017

  The implant is a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery.

• FDA Performs Pre-Approval Inspection of Intersect ENT's Menlo Park Facility

  11/7/2017

  At the conclusion of the inspection, the FDA issued a Form 483 with four inspectional observations.

• Intersect ENT Reports Third Quarter 2017 Results

  11/3/2017

  Third quarter 2017 revenue was $22.3 million, a 21% increase over the third quarter 2016.

• Intersect ENT Announces a Pivotal Study Publication of PROPEL Contour Steroid Releasing Sinus Implant

  11/3/2017

  The study met its primary efficacy endpoint, demonstrating a previously reported statistically significant 65% relative reduction in the need for post-operative interventions.

• Intersect ENT To Report Third Quarter 2017 Financial Results

  10/17/2017

  Intersect ENT, Inc. today announced that it will release financial results for its third quarter on November 2, 2017.

• Intersect ENT Announces Presentation Of Results From RESOLVE II, A Pivotal Phase III Study Evaluating The Safety And Efficacy Of SINUVA, An Investigational Steroid Releasing Sinus Implant

  10/9/2017

• Intersect ENT Announces Presentation Of A Meta-Analysis From Two Randomized Studies Evaluating The Safety And Efficacy Of SINUVA, An Investigational Steroid Releasing Sinus Implant

  9/11/2017

• Intersect ENT Reports Second Quarter 2017 Results

  8/2/2017

• Teresa L. Kline Joins Intersect ENT’s Board Of Directors

  7/21/2017

• Intersect ENT To Report Second Quarter 2017 Financial Results

  7/17/2017

• Intersect ENT Announces PDUFA Date For Office-Based SINUVA Steroid Releasing Sinus Implant

  5/22/2017

• Bay Area's Intersect ENT Gets a PDUFA Date From the FDA for Steroid Releasing Sinus Implant

  5/22/2017

• Intersect ENT Reports First Quarter 2017 Results

  5/3/2017

• Intersect ENT To Report First Quarter 2017 Financial Results

  4/17/2017

• Intersect ENT Submits New Drug Application To FDA For Office-Based RESOLVE Steroid Releasing Implant For Recurrent Chronic Sinus Disease

  3/8/2017

• Intersect ENT Reports Fourth Quarter And Full Year 2016 Results

  3/1/2017

• Bay Area's Intersect ENT Grabs FDA Approval of Newest Steroid Releasing Implant, PROPEL Contour

  2/24/2017

• Intersect ENT To Report Fourth Quarter And Year 2016 Financial Results

  2/6/2017

• Intersect ENT Schedules Third Quarter 2016 Earnings Release And Conference Call For November 2, 2016

  10/19/2016

• Intersect ENT Announces Positive Clinical Results Of Pivotal Study Of RESOLVE In-Office Steroid Releasing Implant

  10/17/2016